Abstracts tagged "SLE and atherosclerosis"

Abstract Number: 2873 • 2016 ACR/ARHP Annual Meeting
B-Cell activating Factor Genetic Variants in Systemic Lupus Erythematosus and Lupus Related Atherosclerosis
Evangelos Theodorou¹, Adrianos Nezos², Pinelopi Kostantopoulou³, Maria Tektonidou⁴, Michael Koutsilieris⁵ and Clio P. Mavragani⁵, ¹Rheumatology, 251 Hellenic (Greek) Air Force Hospital, Athens, Greece, ²Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ³Rheumatology Department, General Hospital of Athens "G.Gennimatas", Αthens, Greece, ⁴Laikon Hospital, Athens University Medical School, Athens, Greece, ⁵Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with an increased atherosclerotic risk compared to healthy population, partially explained by traditional cardiovascular…
Abstract Number: 742 • 2015 ACR/ARHP Annual Meeting
IgM Antibodies Against Malondialdehyde and Phosphorylcholine Are T Cell Dependent and Strong Protection Markers for Atherosclerosis in SLE
Md Mizanur Rahman¹, Ingiäld Hafström², Anquan Liu¹ and Johan Frostegård¹, ¹Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Rheumatology unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Atherosclerosis is characterized by activated immune competent cells and lipid oxidation, where two major epitopes forming adducts are phosphorylcholine (PC) and malondialdehyde (MDA).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].